Goldman Sachs is resuming coverage on shares of Onyx Pharmaceuticals, Inc. with a Neutral rating and a $40 price target.
118555
Goldman Sachs resumes coverage on Onyx Pharmaceuticals
110226
Ladenburg Thalmann cuts price target on Goldman Sachs (gs) to $70
2588
Bond prices recover on fresh demand, call rate eases
157278
Share prices open firmer
57531
Baxter declares quarterly dividend of $0.335 per common share
3391
Rona could receive $143 million by resetting rate for preferred shares
66069
Targacept publicly offering 2.2 million shares
54018
Goldman trying best to cover up the losses
65060
Club Med returns to profit
67086
Sensex recovers partially;
169072
Goldman Sachs declares preferred stock dividends
64947
Pharmasset publicly offers $92.8 million in stock
160436
Shares of Disney (dis) are up 0.6% to $65.44 premarket after the company announces a deal with
157740
Select Medical Holdings Corp. enters oversold territory
122790
Gold shows signs of recovery
71073
Greek shares gently rebound in early afternoon, led up by Intralot
26683
Equity, balanced funds recover